SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-015313
Filing Date
2023-05-19
Accepted
2023-05-19 16:31:13
Documents
14
Period of Report
2023-05-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20230519_8k.htm   iXBRL 8-K 35685
2 EXHIBIT 10.1 ex_523802.htm EX-10.1 60096
  Complete submission text file 0001437749-23-015313.txt   241722

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dffn-20230515.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20230515_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20230515_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20230515_pre.xml EX-101.PRE 11688
8 EXTRACTED XBRL INSTANCE DOCUMENT dffn20230519_8k_htm.xml XML 2577
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 23940739
SIC: 2834 Pharmaceutical Preparations